Summary#
H.R. 11141 would require the DEA Administrator to exempt buprenorphine from the Suspicious Orders Report System for the remainder of the opioid public health emergency. It is before House committees and is not law; the title does not identify an Act it would amend.
- The Administrator would have to make the exemption; the bill describes it as temporary.
- The exemption would last for the rest of the emergency, but the title does not say when that period ends.
What it means for you#
- DEA Administrator: Would have to exempt buprenorphine from the system.
- Businesses handling buprenorphine: The exemption could remove buprenorphine orders from this reporting system. Who is covered and exactly which reporting duties would end are unclear.
- People who use buprenorphine: The bill does not directly change eligibility for treatment, coverage, or access to the drug.
Money#
No publicly available information.
- No publicly available information about federal costs or savings, or changes to businesses’ compliance costs.
What is unclear#
- No publicly available information about the bill’s detailed rules or which orders and businesses the exemption would cover.
- The bill’s title does not explain how the exemption would interact with other reporting or oversight requirements.
- No publicly available information about when the opioid public health emergency ends.
Case for#
- A temporary exemption could reduce reporting burdens for businesses handling buprenorphine during the emergency. As an inference, simpler reporting may make distribution less administratively difficult without permanently changing the system.
Case against#
- Exempting buprenorphine from suspicious-order reporting could give the DEA less information about unusual orders for the drug. As an inference, that could make suspicious activity harder to detect during the emergency.